nodes	percent_of_prediction	percent_of_DWPC	metapath
Methylergometrine—CYP3A4—Rosuvastatin—atherosclerosis	0.0738	0.211	CbGbCtD
Methylergometrine—CYP3A4—Ezetimibe—atherosclerosis	0.0738	0.211	CbGbCtD
Methylergometrine—CYP3A4—Simvastatin—atherosclerosis	0.0686	0.196	CbGbCtD
Methylergometrine—CYP3A4—Lovastatin—atherosclerosis	0.0671	0.192	CbGbCtD
Methylergometrine—CYP3A4—Pravastatin—atherosclerosis	0.0671	0.192	CbGbCtD
Methylergometrine—HTR2A—arteriole—atherosclerosis	0.00813	0.282	CbGeAlD
Methylergometrine—Cramps of lower extremities—Niacin—atherosclerosis	0.00643	0.0281	CcSEcCtD
Methylergometrine—Haematuria—Rosuvastatin—atherosclerosis	0.00513	0.0224	CcSEcCtD
Methylergometrine—HTR2A—vein—atherosclerosis	0.00485	0.168	CbGeAlD
Methylergometrine—Angina pectoris—Niacin—atherosclerosis	0.00428	0.0187	CcSEcCtD
Methylergometrine—Sweating increased—Pravastatin—atherosclerosis	0.00421	0.0184	CcSEcCtD
Methylergometrine—Angina pectoris—Pravastatin—atherosclerosis	0.00421	0.0184	CcSEcCtD
Methylergometrine—Muscle spasms—Lovastatin—atherosclerosis	0.00342	0.015	CcSEcCtD
Methylergometrine—Nervous system disorder—Rosuvastatin—atherosclerosis	0.00336	0.0147	CcSEcCtD
Methylergometrine—Muscle spasms—Ezetimibe—atherosclerosis	0.00336	0.0147	CcSEcCtD
Methylergometrine—Tinnitus—Niacin—atherosclerosis	0.00328	0.0143	CcSEcCtD
Methylergometrine—Tinnitus—Pravastatin—atherosclerosis	0.00323	0.0141	CcSEcCtD
Methylergometrine—HTR2A—hindlimb—atherosclerosis	0.00322	0.112	CbGeAlD
Methylergometrine—Cardiac disorder—Pravastatin—atherosclerosis	0.00321	0.014	CcSEcCtD
Methylergometrine—Muscle spasms—Simvastatin—atherosclerosis	0.0032	0.014	CcSEcCtD
Methylergometrine—Palpitations—Ezetimibe—atherosclerosis	0.00309	0.0135	CcSEcCtD
Methylergometrine—Paraesthesia—Rosuvastatin—atherosclerosis	0.00308	0.0134	CcSEcCtD
Methylergometrine—Chest pain—Lovastatin—atherosclerosis	0.00303	0.0132	CcSEcCtD
Methylergometrine—Hypertension—Ezetimibe—atherosclerosis	0.00302	0.0132	CcSEcCtD
Methylergometrine—Chest pain—Ezetimibe—atherosclerosis	0.00297	0.013	CcSEcCtD
Methylergometrine—Muscle spasms—Niacin—atherosclerosis	0.00294	0.0128	CcSEcCtD
Methylergometrine—Anaphylactic shock—Lovastatin—atherosclerosis	0.00291	0.0127	CcSEcCtD
Methylergometrine—Muscle spasms—Pravastatin—atherosclerosis	0.0029	0.0126	CcSEcCtD
Methylergometrine—Anaphylactic shock—Ezetimibe—atherosclerosis	0.00285	0.0124	CcSEcCtD
Methylergometrine—Chest pain—Simvastatin—atherosclerosis	0.00284	0.0124	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.0028	0.0122	CcSEcCtD
Methylergometrine—Nervous system disorder—Ezetimibe—atherosclerosis	0.0028	0.0122	CcSEcCtD
Methylergometrine—HTR2A—appendage—atherosclerosis	0.00276	0.0958	CbGeAlD
Methylergometrine—Anaphylactic shock—Simvastatin—atherosclerosis	0.00272	0.0119	CcSEcCtD
Methylergometrine—Abdominal pain—Rosuvastatin—atherosclerosis	0.00271	0.0118	CcSEcCtD
Methylergometrine—Palpitations—Niacin—atherosclerosis	0.0027	0.0118	CcSEcCtD
Methylergometrine—Paraesthesia—Lovastatin—atherosclerosis	0.00261	0.0114	CcSEcCtD
Methylergometrine—Hypertension—Pravastatin—atherosclerosis	0.0026	0.0114	CcSEcCtD
Methylergometrine—Dyspnoea—Lovastatin—atherosclerosis	0.00259	0.0113	CcSEcCtD
Methylergometrine—Chest pain—Pravastatin—atherosclerosis	0.00256	0.0112	CcSEcCtD
Methylergometrine—Paraesthesia—Ezetimibe—atherosclerosis	0.00256	0.0112	CcSEcCtD
Methylergometrine—Dyspnoea—Ezetimibe—atherosclerosis	0.00254	0.0111	CcSEcCtD
Methylergometrine—Anaphylactic shock—Niacin—atherosclerosis	0.0025	0.0109	CcSEcCtD
Methylergometrine—Anaphylactic shock—Pravastatin—atherosclerosis	0.00246	0.0107	CcSEcCtD
Methylergometrine—Paraesthesia—Simvastatin—atherosclerosis	0.00244	0.0107	CcSEcCtD
Methylergometrine—Tachycardia—Niacin—atherosclerosis	0.00244	0.0106	CcSEcCtD
Methylergometrine—Dyspnoea—Simvastatin—atherosclerosis	0.00242	0.0106	CcSEcCtD
Methylergometrine—Hyperhidrosis—Niacin—atherosclerosis	0.00241	0.0105	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Lovastatin—atherosclerosis	0.00238	0.0104	CcSEcCtD
Methylergometrine—Hyperhidrosis—Pravastatin—atherosclerosis	0.00238	0.0104	CcSEcCtD
Methylergometrine—Diarrhoea—Rosuvastatin—atherosclerosis	0.00235	0.0102	CcSEcCtD
Methylergometrine—Hypotension—Niacin—atherosclerosis	0.00233	0.0102	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.00233	0.0102	CcSEcCtD
Methylergometrine—Abdominal pain—Lovastatin—atherosclerosis	0.0023	0.01	CcSEcCtD
Methylergometrine—Dizziness—Rosuvastatin—atherosclerosis	0.00227	0.0099	CcSEcCtD
Methylergometrine—Abdominal pain—Ezetimibe—atherosclerosis	0.00225	0.00984	CcSEcCtD
Methylergometrine—Paraesthesia—Niacin—atherosclerosis	0.00224	0.00979	CcSEcCtD
Methylergometrine—Dyspnoea—Niacin—atherosclerosis	0.00223	0.00972	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Simvastatin—atherosclerosis	0.00222	0.00971	CcSEcCtD
Methylergometrine—Paraesthesia—Pravastatin—atherosclerosis	0.00221	0.00964	CcSEcCtD
Methylergometrine—Dyspnoea—Pravastatin—atherosclerosis	0.00219	0.00957	CcSEcCtD
Methylergometrine—Rash—Rosuvastatin—atherosclerosis	0.00216	0.00944	CcSEcCtD
Methylergometrine—Dermatitis—Rosuvastatin—atherosclerosis	0.00216	0.00943	CcSEcCtD
Methylergometrine—Abdominal pain—Simvastatin—atherosclerosis	0.00215	0.00938	CcSEcCtD
Methylergometrine—Headache—Rosuvastatin—atherosclerosis	0.00215	0.00938	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Niacin—atherosclerosis	0.00204	0.00891	CcSEcCtD
Methylergometrine—Nausea—Rosuvastatin—atherosclerosis	0.00204	0.0089	CcSEcCtD
Methylergometrine—Gastrointestinal pain—Pravastatin—atherosclerosis	0.00201	0.00878	CcSEcCtD
Methylergometrine—Diarrhoea—Lovastatin—atherosclerosis	0.00199	0.00868	CcSEcCtD
Methylergometrine—HTR2A—artery—atherosclerosis	0.00197	0.0685	CbGeAlD
Methylergometrine—Abdominal pain—Niacin—atherosclerosis	0.00197	0.00862	CcSEcCtD
Methylergometrine—Diarrhoea—Ezetimibe—atherosclerosis	0.00195	0.00852	CcSEcCtD
Methylergometrine—Abdominal pain—Pravastatin—atherosclerosis	0.00194	0.00848	CcSEcCtD
Methylergometrine—Dizziness—Lovastatin—atherosclerosis	0.00192	0.00839	CcSEcCtD
Methylergometrine—Dizziness—Ezetimibe—atherosclerosis	0.00189	0.00823	CcSEcCtD
Methylergometrine—Diarrhoea—Simvastatin—atherosclerosis	0.00186	0.00812	CcSEcCtD
Methylergometrine—Vomiting—Lovastatin—atherosclerosis	0.00185	0.00807	CcSEcCtD
Methylergometrine—Rash—Lovastatin—atherosclerosis	0.00183	0.008	CcSEcCtD
Methylergometrine—Dermatitis—Lovastatin—atherosclerosis	0.00183	0.00799	CcSEcCtD
Methylergometrine—Headache—Lovastatin—atherosclerosis	0.00182	0.00795	CcSEcCtD
Methylergometrine—Vomiting—Ezetimibe—atherosclerosis	0.00181	0.00791	CcSEcCtD
Methylergometrine—Dizziness—Simvastatin—atherosclerosis	0.0018	0.00785	CcSEcCtD
Methylergometrine—Rash—Ezetimibe—atherosclerosis	0.0018	0.00785	CcSEcCtD
Methylergometrine—Dermatitis—Ezetimibe—atherosclerosis	0.0018	0.00784	CcSEcCtD
Methylergometrine—Headache—Ezetimibe—atherosclerosis	0.00179	0.0078	CcSEcCtD
Methylergometrine—Vomiting—Simvastatin—atherosclerosis	0.00173	0.00755	CcSEcCtD
Methylergometrine—Nausea—Lovastatin—atherosclerosis	0.00173	0.00754	CcSEcCtD
Methylergometrine—Rash—Simvastatin—atherosclerosis	0.00171	0.00749	CcSEcCtD
Methylergometrine—Dermatitis—Simvastatin—atherosclerosis	0.00171	0.00748	CcSEcCtD
Methylergometrine—Diarrhoea—Niacin—atherosclerosis	0.00171	0.00746	CcSEcCtD
Methylergometrine—Headache—Simvastatin—atherosclerosis	0.0017	0.00744	CcSEcCtD
Methylergometrine—Nausea—Ezetimibe—atherosclerosis	0.00169	0.00739	CcSEcCtD
Methylergometrine—Diarrhoea—Pravastatin—atherosclerosis	0.00168	0.00734	CcSEcCtD
Methylergometrine—HTR2A—endothelium—atherosclerosis	0.00167	0.0578	CbGeAlD
Methylergometrine—Dizziness—Niacin—atherosclerosis	0.00165	0.00721	CcSEcCtD
Methylergometrine—Dizziness—Pravastatin—atherosclerosis	0.00163	0.0071	CcSEcCtD
Methylergometrine—Nausea—Simvastatin—atherosclerosis	0.00161	0.00705	CcSEcCtD
Methylergometrine—Vomiting—Niacin—atherosclerosis	0.00159	0.00693	CcSEcCtD
Methylergometrine—Rash—Niacin—atherosclerosis	0.00157	0.00687	CcSEcCtD
Methylergometrine—Dermatitis—Niacin—atherosclerosis	0.00157	0.00687	CcSEcCtD
Methylergometrine—Headache—Niacin—atherosclerosis	0.00156	0.00683	CcSEcCtD
Methylergometrine—Vomiting—Pravastatin—atherosclerosis	0.00156	0.00682	CcSEcCtD
Methylergometrine—Rash—Pravastatin—atherosclerosis	0.00155	0.00677	CcSEcCtD
Methylergometrine—Dermatitis—Pravastatin—atherosclerosis	0.00155	0.00676	CcSEcCtD
Methylergometrine—Headache—Pravastatin—atherosclerosis	0.00154	0.00672	CcSEcCtD
Methylergometrine—HTR2A—blood vessel—atherosclerosis	0.00154	0.0533	CbGeAlD
Methylergometrine—Nausea—Niacin—atherosclerosis	0.00148	0.00647	CcSEcCtD
Methylergometrine—Nausea—Pravastatin—atherosclerosis	0.00146	0.00638	CcSEcCtD
Methylergometrine—HTR2B—cardiovascular system—atherosclerosis	0.00128	0.0445	CbGeAlD
Methylergometrine—HTR2B—adipose tissue—atherosclerosis	0.00113	0.0393	CbGeAlD
Methylergometrine—HTR2A—connective tissue—atherosclerosis	0.000789	0.0273	CbGeAlD
Methylergometrine—HTR2A—cardiovascular system—atherosclerosis	0.000686	0.0238	CbGeAlD
Methylergometrine—HTR2A—liver—atherosclerosis	0.000424	0.0147	CbGeAlD
Methylergometrine—CYP3A4—liver—atherosclerosis	0.000393	0.0136	CbGeAlD
Methylergometrine—HTR2A—Signaling Pathways—CCL3—atherosclerosis	7.76e-05	0.000198	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP3—atherosclerosis	7.59e-05	0.000194	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—F2—atherosclerosis	7.56e-05	0.000193	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IGF2—atherosclerosis	7.56e-05	0.000193	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NOS3—atherosclerosis	7.48e-05	0.000191	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NCF1—atherosclerosis	7.43e-05	0.00019	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SOCS3—atherosclerosis	7.41e-05	0.000189	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—SERPINE1—atherosclerosis	7.39e-05	0.000189	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOB—atherosclerosis	7.34e-05	0.000187	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—CXCL8—atherosclerosis	7.27e-05	0.000186	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—PIK3CG—atherosclerosis	7.24e-05	0.000185	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—F2—atherosclerosis	7.23e-05	0.000185	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—EDN1—atherosclerosis	7.22e-05	0.000184	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL5—atherosclerosis	7.16e-05	0.000183	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP3—atherosclerosis	7.16e-05	0.000183	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IGF2—atherosclerosis	7.13e-05	0.000182	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AGT—atherosclerosis	7.11e-05	0.000181	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NOS3—atherosclerosis	7.06e-05	0.00018	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCR2—atherosclerosis	7.02e-05	0.000179	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EDNRA—atherosclerosis	7.02e-05	0.000179	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—LPL—atherosclerosis	7.01e-05	0.000179	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CYBA—atherosclerosis	6.99e-05	0.000178	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—PIK3CG—atherosclerosis	6.92e-05	0.000177	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOB—atherosclerosis	6.92e-05	0.000177	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—KNG1—atherosclerosis	6.91e-05	0.000177	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AGTR1—atherosclerosis	6.87e-05	0.000175	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—CXCL8—atherosclerosis	6.86e-05	0.000175	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PLAT—atherosclerosis	6.84e-05	0.000175	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—GHRL—atherosclerosis	6.84e-05	0.000175	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PARP1—atherosclerosis	6.84e-05	0.000175	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PRKCG—atherosclerosis	6.81e-05	0.000174	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—EDN1—atherosclerosis	6.81e-05	0.000174	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL5—atherosclerosis	6.76e-05	0.000173	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CCL2—atherosclerosis	6.74e-05	0.000172	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PLG—atherosclerosis	6.7e-05	0.000171	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SPP1—atherosclerosis	6.64e-05	0.000169	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—CXCL8—atherosclerosis	6.63e-05	0.000169	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—LPL—atherosclerosis	6.61e-05	0.000169	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—CXCL8—atherosclerosis	6.61e-05	0.000169	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—F2—atherosclerosis	6.57e-05	0.000168	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PRKCG—atherosclerosis	6.42e-05	0.000164	CbGpPWpGaD
Methylergometrine—HTR1F—GPCR downstream signaling—AKT1—atherosclerosis	6.41e-05	0.000164	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SOCS3—atherosclerosis	6.34e-05	0.000162	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—IL6—atherosclerosis	6.31e-05	0.000161	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—PIK3CG—atherosclerosis	6.29e-05	0.00016	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—CXCL8—atherosclerosis	6.26e-05	0.00016	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SPP1—atherosclerosis	6.26e-05	0.00016	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—CXCL8—atherosclerosis	6.23e-05	0.000159	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCG1—atherosclerosis	6.19e-05	0.000158	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PDGFB—atherosclerosis	6.14e-05	0.000157	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP3—atherosclerosis	6.12e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF2—atherosclerosis	6.1e-05	0.000156	CbGpPWpGaD
Methylergometrine—HTR1E—GPCR downstream signaling—AKT1—atherosclerosis	6.05e-05	0.000154	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—KNG1—atherosclerosis	6e-05	0.000153	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MMP9—atherosclerosis	6e-05	0.000153	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AGT—atherosclerosis	5.99e-05	0.000153	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AGTR1—atherosclerosis	5.97e-05	0.000152	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—IL6—atherosclerosis	5.95e-05	0.000152	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—NFKB1—atherosclerosis	5.94e-05	0.000152	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOB—atherosclerosis	5.92e-05	0.000151	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—LEP—atherosclerosis	5.87e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOE—atherosclerosis	5.87e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—CXCL8—atherosclerosis	5.87e-05	0.00015	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CCL2—atherosclerosis	5.85e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MAPK8—atherosclerosis	5.84e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—EDN1—atherosclerosis	5.83e-05	0.000149	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LCAT—atherosclerosis	5.82e-05	0.000149	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—FABP4—atherosclerosis	5.82e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling by GPCR—AKT1—atherosclerosis	5.82e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CAV1—atherosclerosis	5.82e-05	0.000149	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PLG—atherosclerosis	5.81e-05	0.000148	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—APOA1—atherosclerosis	5.8e-05	0.000148	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PDGFB—atherosclerosis	5.79e-05	0.000148	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL5—atherosclerosis	5.78e-05	0.000148	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA4—atherosclerosis	5.71e-05	0.000146	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MMP9—atherosclerosis	5.66e-05	0.000145	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AGT—atherosclerosis	5.65e-05	0.000144	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—LPL—atherosclerosis	5.65e-05	0.000144	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP7A1—atherosclerosis	5.61e-05	0.000143	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—ESR1—atherosclerosis	5.61e-05	0.000143	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—NFKB1—atherosclerosis	5.6e-05	0.000143	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—LEP—atherosclerosis	5.54e-05	0.000141	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—F2—atherosclerosis	5.54e-05	0.000141	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOE—atherosclerosis	5.54e-05	0.000141	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SOCS3—atherosclerosis	5.51e-05	0.000141	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MAPK8—atherosclerosis	5.51e-05	0.000141	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PRKCG—atherosclerosis	5.5e-05	0.00014	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling by GPCR—AKT1—atherosclerosis	5.49e-05	0.00014	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CAV1—atherosclerosis	5.49e-05	0.00014	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—APOA1—atherosclerosis	5.47e-05	0.00014	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—VEGFA—atherosclerosis	5.39e-05	0.000138	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SPP1—atherosclerosis	5.35e-05	0.000137	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—STAT3—atherosclerosis	5.34e-05	0.000136	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—CXCL8—atherosclerosis	5.33e-05	0.000136	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP3—atherosclerosis	5.32e-05	0.000136	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—PIK3CG—atherosclerosis	5.3e-05	0.000135	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF2—atherosclerosis	5.29e-05	0.000135	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—ESR1—atherosclerosis	5.29e-05	0.000135	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—F2—atherosclerosis	5.22e-05	0.000133	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CYP27A1—atherosclerosis	5.19e-05	0.000133	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOB—atherosclerosis	5.14e-05	0.000131	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—MAPK3—atherosclerosis	5.1e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—CXCL8—atherosclerosis	5.1e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—VEGFA—atherosclerosis	5.08e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—MAPK3—atherosclerosis	5.08e-05	0.00013	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—EDN1—atherosclerosis	5.06e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—STAT3—atherosclerosis	5.03e-05	0.000129	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL5—atherosclerosis	5.02e-05	0.000128	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—INS—atherosclerosis	5.02e-05	0.000128	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—PIK3CG—atherosclerosis	5e-05	0.000128	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PDGFB—atherosclerosis	4.95e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—TGFB1—atherosclerosis	4.95e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CCL2—atherosclerosis	4.94e-05	0.000126	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PLA2G2A—atherosclerosis	4.92e-05	0.000126	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA2—atherosclerosis	4.92e-05	0.000126	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALOX15—atherosclerosis	4.92e-05	0.000126	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALOX5AP—atherosclerosis	4.92e-05	0.000126	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—LPL—atherosclerosis	4.91e-05	0.000125	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCG5—atherosclerosis	4.86e-05	0.000124	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IGF1—atherosclerosis	4.85e-05	0.000124	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AGT—atherosclerosis	4.84e-05	0.000123	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—MAPK3—atherosclerosis	4.81e-05	0.000123	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—MAPK3—atherosclerosis	4.79e-05	0.000122	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PRKCG—atherosclerosis	4.77e-05	0.000122	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—LEP—atherosclerosis	4.74e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOE—atherosclerosis	4.74e-05	0.000121	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—INS—atherosclerosis	4.73e-05	0.000121	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CAV1—atherosclerosis	4.69e-05	0.00012	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LPA—atherosclerosis	4.69e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—APOA1—atherosclerosis	4.68e-05	0.00012	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—TGFB1—atherosclerosis	4.67e-05	0.000119	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CCL2—atherosclerosis	4.65e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SPP1—atherosclerosis	4.65e-05	0.000119	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—CXCL8—atherosclerosis	4.63e-05	0.000118	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—SERPINE1—atherosclerosis	4.61e-05	0.000118	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IGF1—atherosclerosis	4.58e-05	0.000117	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—BGN—atherosclerosis	4.54e-05	0.000116	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—ESR1—atherosclerosis	4.52e-05	0.000115	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA5—atherosclerosis	4.5e-05	0.000115	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—F2—atherosclerosis	4.47e-05	0.000114	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NOS3—atherosclerosis	4.4e-05	0.000112	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—SERPINE1—atherosclerosis	4.35e-05	0.000111	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	4.33e-05	0.000111	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PDGFB—atherosclerosis	4.3e-05	0.00011	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	4.28e-05	0.000109	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AGT—atherosclerosis	4.2e-05	0.000107	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALOX5—atherosclerosis	4.18e-05	0.000107	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NOS3—atherosclerosis	4.15e-05	0.000106	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—LEP—atherosclerosis	4.11e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOE—atherosclerosis	4.11e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	4.09e-05	0.000105	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CAV1—atherosclerosis	4.08e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—APOA1—atherosclerosis	4.07e-05	0.000104	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—INS—atherosclerosis	4.05e-05	0.000103	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CCL2—atherosclerosis	3.98e-05	0.000102	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—ESR1—atherosclerosis	3.93e-05	0.0001	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IGF1—atherosclerosis	3.91e-05	0.0001	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—CXCL8—atherosclerosis	3.9e-05	9.96e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—F2—atherosclerosis	3.88e-05	9.91e-05	CbGpPWpGaD
Methylergometrine—HTR2B—GPCR downstream signaling—AKT1—atherosclerosis	3.77e-05	9.63e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NAMPT—atherosclerosis	3.75e-05	9.58e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LIPC—atherosclerosis	3.73e-05	9.52e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—IL6—atherosclerosis	3.73e-05	9.52e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	3.72e-05	9.49e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—PIK3CG—atherosclerosis	3.71e-05	9.48e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—IL6—atherosclerosis	3.71e-05	9.48e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOC3—atherosclerosis	3.7e-05	9.46e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LDLR—atherosclerosis	3.68e-05	9.4e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—CXCL8—atherosclerosis	3.68e-05	9.4e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CETP—atherosclerosis	3.6e-05	9.18e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—MAPK3—atherosclerosis	3.56e-05	9.08e-05	CbGpPWpGaD
Methylergometrine—DRD1—GPCR downstream signaling—AKT1—atherosclerosis	3.56e-05	9.08e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NOS3—atherosclerosis	3.55e-05	9.06e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MMP9—atherosclerosis	3.53e-05	9.01e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—IL6—atherosclerosis	3.52e-05	8.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—INS—atherosclerosis	3.51e-05	8.97e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—IL6—atherosclerosis	3.5e-05	8.94e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—NFKB1—atherosclerosis	3.49e-05	8.92e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CCL2—atherosclerosis	3.46e-05	8.83e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—SCARB1—atherosclerosis	3.44e-05	8.8e-05	CbGpPWpGaD
Methylergometrine—HTR1F—Signaling Pathways—AKT1—atherosclerosis	3.44e-05	8.78e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAPK8—atherosclerosis	3.43e-05	8.77e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling by GPCR—AKT1—atherosclerosis	3.42e-05	8.74e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IGF1—atherosclerosis	3.4e-05	8.68e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MMP9—atherosclerosis	3.33e-05	8.5e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—NFKB1—atherosclerosis	3.29e-05	8.41e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HMGCR—atherosclerosis	3.25e-05	8.31e-05	CbGpPWpGaD
Methylergometrine—HTR1E—Signaling Pathways—AKT1—atherosclerosis	3.24e-05	8.28e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAPK8—atherosclerosis	3.24e-05	8.27e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling by GPCR—AKT1—atherosclerosis	3.23e-05	8.24e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—SERPINE1—atherosclerosis	3.23e-05	8.24e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—VEGFA—atherosclerosis	3.17e-05	8.09e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.15e-05	8.04e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—STAT3—atherosclerosis	3.14e-05	8.01e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NOS3—atherosclerosis	3.08e-05	7.87e-05	CbGpPWpGaD
Methylergometrine—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.04e-05	7.77e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—MAPK3—atherosclerosis	3e-05	7.66e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—IL6—atherosclerosis	2.99e-05	7.64e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—VEGFA—atherosclerosis	2.99e-05	7.63e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—STAT3—atherosclerosis	2.96e-05	7.56e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—TGFB1—atherosclerosis	2.91e-05	7.43e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ABCA1—atherosclerosis	2.9e-05	7.4e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MMP9—atherosclerosis	2.85e-05	7.27e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—MAPK3—atherosclerosis	2.83e-05	7.22e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	2.82e-05	7.19e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	2.77e-05	7.07e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	2.76e-05	7.05e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—TGFB1—atherosclerosis	2.74e-05	7.01e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—CXCL8—atherosclerosis	2.73e-05	6.98e-05	CbGpPWpGaD
Methylergometrine—HTR2A—GPCR downstream signaling—AKT1—atherosclerosis	2.64e-05	6.74e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—IL6—atherosclerosis	2.6e-05	6.64e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	2.56e-05	6.53e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—STAT3—atherosclerosis	2.53e-05	6.46e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—HMOX1—atherosclerosis	2.49e-05	6.35e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MMP9—atherosclerosis	2.47e-05	6.31e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—NFKB1—atherosclerosis	2.45e-05	6.25e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	2.42e-05	6.18e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK8—atherosclerosis	2.4e-05	6.14e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling by GPCR—AKT1—atherosclerosis	2.4e-05	6.12e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOB—atherosclerosis	2.38e-05	6.08e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.35e-05	5.99e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.32e-05	5.92e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—LPL—atherosclerosis	2.28e-05	5.81e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—VEGFA—atherosclerosis	2.22e-05	5.67e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—GPX1—atherosclerosis	2.22e-05	5.67e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—STAT3—atherosclerosis	2.2e-05	5.61e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—IL6—atherosclerosis	2.19e-05	5.6e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CD36—atherosclerosis	2.16e-05	5.52e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—MAPK3—atherosclerosis	2.1e-05	5.36e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—IL6—atherosclerosis	2.07e-05	5.28e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.05e-05	5.23e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—TGFB1—atherosclerosis	2.04e-05	5.2e-05	CbGpPWpGaD
Methylergometrine—HTR2B—Signaling Pathways—AKT1—atherosclerosis	2.02e-05	5.16e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARA—atherosclerosis	2.01e-05	5.13e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AGT—atherosclerosis	1.95e-05	4.97e-05	CbGpPWpGaD
Methylergometrine—DRD1—Signaling Pathways—AKT1—atherosclerosis	1.91e-05	4.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOE—atherosclerosis	1.91e-05	4.87e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—CAV1—atherosclerosis	1.89e-05	4.82e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—APOA1—atherosclerosis	1.89e-05	4.81e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—IL6—atherosclerosis	1.77e-05	4.52e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PIK3CG—atherosclerosis	1.72e-05	4.39e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PPARG—atherosclerosis	1.66e-05	4.24e-05	CbGpPWpGaD
Methylergometrine—HTR2C—Signaling Pathways—AKT1—atherosclerosis	1.63e-05	4.17e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—INS—atherosclerosis	1.63e-05	4.16e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—IL6—atherosclerosis	1.54e-05	3.92e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—ALB—atherosclerosis	1.49e-05	3.81e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—NOS3—atherosclerosis	1.43e-05	3.65e-05	CbGpPWpGaD
Methylergometrine—HTR2A—Signaling Pathways—AKT1—atherosclerosis	1.42e-05	3.62e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.31e-05	3.34e-05	CbGpPWpGaD
Methylergometrine—CYP3A4—Metabolism—AKT1—atherosclerosis	6.57e-06	1.68e-05	CbGpPWpGaD
